Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Cancer Research

• Publication date

  1990-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 2123740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor

  2004cited by this paper
• Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth

  2004cited by this paper
• Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models

  2004cited by this paper
• Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers

  2004cited by this paper
• Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.

  1990cited by this paper
• Recruitment and activation of tumor-specific immune T cells in situ. CD8+ cells predominate the secondary response in sponge matrices and exert both delayed-type hypersensitivity-like and cytotoxic T lymphocyte activity.

  1989cited by this paper
• Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

  1989influential reference
• Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.

  1989influential reference
• Recovery of Activated Cytotoxic T Cells from Minor H Incompatible Tumor Graft Rejection Sites

  1989cited by this paper
• Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

  1988cited by this paper
• Isolation and reactivity of host effectors associated with the manifestation of concomitant tumor immunity.

  1988cited by this paper
• Chemotherapy of mice bearing syngeneic tumors with 1,3-bis (2-chloroethyl)-1-nitrosourea is effective only in normal, but not in irradiated or nude, mice: role of L3T4+ (CD4+) and Lyt-2+ (CD8+) T cells.

  1988cited by this paper
• Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.

  1988influential reference
• Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.

  1988cited by this paper
• Analysis of T cell subsets in normal adults. Comparison of whole blood lysis technique to Ficoll-Hypaque separation by flow cytometry.

  1987cited by this paper
• Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.

  1987cited by this paper
• Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

  1986cited by this paper
• Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma.

  1985influential reference
• Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.

  1985cited by this paper
• Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.

  1984cited by this paper
• Inhibition of the development of suppressor cells in culture by 4-hydroperoxycyclophosphamide

  1984cited by this paper
• Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

  1983cited by this paper
• Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.

  1982cited by this paper
• Selective Effects of Adriamycin on Murine Host Defense Systems

  1982cited by this paper
• Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities.

  1982cited by this paper
• Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.

  1981cited by this paper
• Preparative nonlytic separation of Lyt2+ and Lyt2− T lymphocytes, functional analyses of the separated cells and demonstration of synergy in graft‐vs.‐host reaction of Lyt2+ and Lyt2− cells

  1981cited by this paper
• Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

  1981cited by this paper
• IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.

  1980cited by this paper
• Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.

  1980cited by this paper
• Regulation of specific cell-mediated cytotoxic response against SV40- induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice

  1979cited by this paper
• Xenogeneic Monoclonal Antibodies to Mouse Lymphoid Differentiation Antigens *

  1979cited by this paper
• Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.

  1978cited by this paper
• Cytological and functional analysis of inflammatory infiltrates in human malignant tumors II. Functional investigations of the infiltrating inflammatory cells

  1978cited by this paper
• Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses

  1975cited by this paper
• Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

  1973cited by this paper
• Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig.

  1967cited by this paper

• Combinatorial Immunotherapy and Chemotherapy

  2018cites this paper
• Role of NK cells in DC-based immunotherapy of melanoma

  2011cites this paper
• Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205+ dendritic cells

  2010cites this paper
• Low-Dose Chemotherapy-treated Tumor-bearing Mice Realization of the Therapeutic Potential of CTLA-4 Blockade in Updated Version

  2006cites this paper
• REALIZATION OF ThE THERAPEUTIC BENEFITS OF CFLA-4 BLOCKADE

  2006cites this paper
• ; Realizationof theTherapeuticPotentialof CTLA-4Blockadein Low-Dose Chemotherapy-treated Tumor-bearing Mice1

  2006cites this paper
• Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor

  2006cites this paper
• Ioannides CTL-mediated Lysis Results in Enhanced Drug Sensitivity Increased Sensitivity of Adriamycin-selected Tumor Lines to Updated Version

  2006cites this paper
• Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers

  2005cites this paper
• Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers

  2005cites this paper
• Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers

  2005cites this paper
• Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration

  2005cites this paper
• Inhibition of Tumor-Eradicating Immunity Importance of IL-10 for CTLA-4-Mediated and

  2004influential citation
• Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity1

  2004cites this paper
• Melphalan-induced up-regulation of B7–1 surface expression on normal splenic B cells

  2003cites this paper
• Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model

  2002cites this paper
• Induction of 4‐1BB (CD137) expression by DNA damaging agents in human T lymphocytes

  2002cites this paper
• Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression.

  2001cites this paper
• Melphalan-Induced Expression of IFN-β in MOPC-315 Tumor-Bearing Mice and Its Importance for the Up-Regulation of TNF-α Expression1

  2001cites this paper
• Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity.

  2001cites this paper
• Myeloma‐reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway

  2001cites this paper
• Immunomodulation by anticancer chemotherapy: more is not always better (review).

  2001cites this paper
• B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells

  2000cites this paper
• TumorUp-Regulate B 7-1 Gene Expression in Melphalan and Other Anticancer Modalities and

  2000cites this paper
• Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells1

  2000cites this paper
• Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors

  1999cites this paper
• T‐cell‐epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma

  1999cites this paper
• Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression.

  1999cites this paper
• Norepinephrine-Mediated Inhibition of Antitumor Cytotoxic T Lymphocyte Generation Involves a β-Adrenergic Receptor Mechanism and Decreased TNF-α Gene Expression

  1999cites this paper
• Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.

  1998cites this paper
• Large MOPC-315 Tumor Tumor-Eradicating Immunity by Mice Bearing a Melphalan-Induced Acquisition of Importance of the B 7-2 Molecule for Low Dose

  1998influential citation
• Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor

  1998cites this paper
• Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells.

  1998cites this paper
• Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity.

  1998cites this paper
• Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.

  1998cites this paper
• Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer

  1998cites this paper
• Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.

  1998cites this paper
• Idiotype‐specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets

  1997cites this paper
• Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism.

  1997cites this paper
• Host-Mediated Antitumor Activity Induced by Neocarzinostatin and Its Polymer-Conjugated Derivative SMANCS in Tumor-Bearing Mice

  1997cites this paper
• T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden

  1997cites this paper
• Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.

  1996cites this paper
• Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma

  1995cites this paper
• Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon γ in the therapeutic outcome

  1995cites this paper
• Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.

  1995cites this paper
• Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy

  1994cites this paper
• Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study.

  1994cites this paper
• Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.

  1994cites this paper
• Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor

  1994cites this paper
• Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.

  1994cites this paper
• Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

  1994cites this paper
• Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.

  1994cites this paper
• Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.

  1993cites this paper
• Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan‐treated BALB/C mice bearing a large MOPC‐315 tumor

  1992cites this paper
• Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.

  1992cites this paper
• Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.

  1991cites this paper